Adeagbo A S, Henzel M K
Department of Physiology and Biophysics, School of Medicine, University of Louisville, Ky 40292, USA.
J Vasc Res. 1998 Jan-Feb;35(1):27-35. doi: 10.1159/000025562.
The isolated, perfused rat mesenteric bed releases a cytochrome P450-linked metabolite of arachidonic acid (AA) as endothelium-derived hyperpolarizing factor (EDHF) in response to acetylcholine and histamine. This study assessed the relative contribution of two AA-generating pathways, phospholipase A2 (PLA2) and diacylglycerol (DAG) lipase, to EDHF-mediated dilation of the rat mesenteric bed. We tested the hypothesis that PLA2-mediated release of AA is essential for the production of EDHF. Mesenteric beds were perfused with physiological salt solution (PSS) containing indomethacin and nitro-L-arginine methyl ester to block cyclooxygenase and nitric oxide synthase, respectively, and constricted with cirazoline (an alpha1-adrenoceptor agonist). Bolus applications of acetylcholine and histamine caused dose-dependent dilation of the constricted beds. The 85-kDa PLA2 inhibitor, arachidonyl trifluoromethyl ketone (AACOCF3), at 3 microM, profoundly blunted decreases in perfusion pressure initiated by 1 nmol acetylcholine (94.3+/-1.7%) and by 100 nmol histamine (88.5+/-3.3%) to 9.6+/-7.5 and 8.6+/-6.0%, respectively. AACOCF3 also blocked cirazoline-stimulated release of 6-keto-PG1alpha, but did not alter the vasodilation initiated by sodium nitroprusside (a nitric oxide donor), cromakalim (a K+ channel activator), or by Na+/K+-ATPase activation, as measured by KCl vasodilation in preconstricted beds perfused with K+-free PSS. The 14-kDa PLA2 inhibitor, oleyloxyethyl phosphorylcholine, also blocked EDHF vasodilation and also significantly inhibited K+ channel activity. Neither the Ca2+-independent PLA2 inhibitor, HELSS [E-6-(bromomethylene)-tetrahydro-3-(1-naphthalenyl)-2H-pyran-2-one], nor DAG lipase inhibitor, RHC-80267 [1,6-bis-(cyclohexyloximino-carbonylamino)-hexane] altered EDHF-mediated vasodilation. However, RHC-80267 blocked cirazoline-stimulated release of 6-keto-PGF1alpha. We conclude that Ca2+-dependent PLA2, rather than DAG lipase, generates the AA for the production of EDHF in the perfused rat mesenteric bed.
分离灌注的大鼠肠系膜床在对乙酰胆碱和组胺作出反应时,会释放一种与细胞色素P450相关的花生四烯酸(AA)代谢产物作为内皮源性超极化因子(EDHF)。本研究评估了两种AA生成途径,即磷脂酶A2(PLA2)和二酰基甘油(DAG)脂肪酶,对大鼠肠系膜床EDHF介导的血管舒张的相对贡献。我们检验了以下假设:PLA2介导的AA释放对于EDHF的产生至关重要。用含有吲哚美辛和硝基-L-精氨酸甲酯的生理盐溶液(PSS)灌注肠系膜床,以分别阻断环氧化酶和一氧化氮合酶,并用可乐定(一种α1肾上腺素能受体激动剂)使其收缩。推注乙酰胆碱和组胺会使收缩的肠系膜床产生剂量依赖性舒张。3 μM的85-kDa PLA2抑制剂花生四烯酰三氟甲基酮(AACOCF3)显著减弱了由1 nmol乙酰胆碱(94.3±1.7%)和100 nmol组胺(88.5±3.3%)引发的灌注压下降,分别降至9.6±7.5%和8.6±6.0%。AACOCF3还阻断了可乐定刺激的6-酮-PG1α释放,但不改变硝普钠(一种一氧化氮供体)、克罗卡林(一种钾通道激活剂)引发的血管舒张,或在无钾PSS灌注的预收缩床中通过氯化钾血管舒张所测量的钠钾-ATP酶激活引发的血管舒张。14-kDa PLA2抑制剂油酰氧基乙基磷酰胆碱也阻断了EDHF介导的血管舒张,并且还显著抑制了钾通道活性。无论是不依赖钙的PLA2抑制剂HELSS [E-6-(溴亚甲基)-四氢-3-(1-萘基)-2H-吡喃-2-酮],还是DAG脂肪酶抑制剂RHC-80267 [1,6-双-(环己基肟基羰基氨基)-己烷],都没有改变EDHF介导的血管舒张。然而,RHC-80267阻断了可乐定刺激的6-酮-PGF1α释放。我们得出结论,在灌注的大鼠肠系膜床中,依赖钙的PLA2而非DAG脂肪酶产生用于生成EDHF的AA。